The fundamental basis for immunotherapy of leukemia is that leukemic cells express specific antigens that are not expressed by normal hematopoietic cells. However, the host immune system appears to be tolerant to leukemia cells. To overcome this tolerance, we vaccinated immunocompetent mice with murine leukemia cells (WEHI-3B and BCR-ABL þ 32D cells) transduced with a specifically constructed transmembrane form of granulocytemacrophage colony-stimulating factor (tmGM-CSF). The transduced cells expressed tmGM-CSF on the cellsurface. To determine whether tmGM-CSF-expressing WEHI-3B leukemia cells would prevent leukemia formation as a vaccine, immunocompetent mice (BALB/c and C3H/HEJ) were immunized with lethally irradiated murine leukemia cells expressing cell-surface tmGM-CSF before challenging mice with murine leukemia cells. Two immunocompetent mouse models were investigated, either WEHI-3B cells in BALB/c mice or BCR-ABL þ 32D cells in C3H/HEJ mouse. The results showed that 100% of WEHI-3B/tmGM-CSF-vaccinated BALB/c mice and about 65% of 32D þ BCR-ABL/tmGM-CSFvaccinated C3H/HEJ mice were protected from leukemia after leukemia cell challenge, whereas all non-vaccinated mice succumbed to leukemia. Spleen and marrow cell suspensions from vaccinated mice challenged with WEHI-3B cells lacked detectable GFP þ WEHI-3B cells at 82 days post-challenge. A significant delay of death was observed in C3H/HEJ mice challenged with the very aggressive DA-1 cell line expressing BCR-ABL. Vaccination of mice with WEHI-3B/CD40L cells protected 80% of the mice from the WEHI-3B challenge. Notably, 60% of the WEHI-3B/BALB/c mice were also protected from leukemia when WEHI-3B/tmGM-CSF vaccination was carried out after the leukemia challenge. In order to determine whether cellular immunity is involved in this vaccine-mediated protection, either CD4 þ or CD8 þ T cells were depleted from mice after the WEHI-3B/tmGM-CSF vaccination. The results indicate that CD8 þ T-cells mediated the protective immune response provided by the irradiated tmGM-CSF-expressing WEHI-3B cells.
Introduction
The fundamental basis of immunotherapy for leukemia is based on the concept that leukemic cells express immunogens that can lead to the host immune responses (Galea-Lauri, 2002; Acres et al., 2004; Bitton, 2004) . Increasing evidence has indicated that the immune system can play a role in the destruction of leukemic cells if immune system is stimulated appropriately by cytokines such as interleukin-2 and GM-CSF, which can lead to an improvement of overall survival of leukemic patients (Rojas et al., 2003; Fujimura et al., 2004) . The fact that bone marrow transplantation with allogeneic cells causes graft versus leukemia provides strong evidence that the host immune system is capable of controlling leukemia (Butturini and Gale, 1995; Platzbecker et al., 2004) . These and other findings (O'Keefe et al., 2004) suggest that impairment of leukemia-specific immune responses occurs in leukemia patients, and this abnormality may be due to oncoproteins, such as BcrAbl in chronic myeloid leukemia, which cause immune dysfunction in hematopoietic cells (Dong et al., 2003) .
In vitro studies have demonstrated that cytokines like GM-CSF stimulate functional maturation of antigenpresenting cells [e.g. dendritic cells (DCs)] (Bleier et al., 2004; Pulendran et al., 2004) . As GM-CSF is a secreted molecule, it has been proposed that GM-CSF could be more efficient in stimulating maturation of antigenpresenting cells if it can be anchored on the surface of cancer cells (Larregina et al., 1996; Soo Hoo et al., 1999; Yei et al., 2002; ) . In this regard, transmembrane-bound GM-CSF has a better effect in stimulating immune response than secreted GM-CSF in melanoma (Soo Hoo et al., 1999; Yei et al., 2002) . However, no information is available regarding the anti-leukemia effects of tmGM-CSF as an immunotherapy approach in leukemia.
In order to test our hypothesis that forced-expressing tmGM-CSF on the surface of leukemia cells acts as an efficient stimulator of the host cellular immunity, we adopted murine leukemia models in immunocompetent BALB/c and C3H/HEJ mice. For BALB/c mouse, leukemia was induced by WEHI-3B cells, a spontaneous monocytic leukemic cell (de Vos et al., 1998) that was originally derived from the BALB/c mouse strain. For the C3H/HEJ strain, the leukemia was induced by either BCR-ABL þ 32D cells (32D cells were originally derived from this strain; Zhao et al., 1997) or the more aggressive BCR-ABL þ DA1 cell line (Vereecque et al., 1999) .
Results
Transmembrane form of GM-CSF and CD40L expression in murine leukemia cells WEHI-3B cells were transduced by infection with a bicistronic lentivirus encoding either tmGM-CSF/green fluorescent protein (GFP) and GM-CSF/GFP (Figure 1 ). Cells were sorted by monitoring GFP þ cells for cell-surface-anchored GM-CSF expression. Flow cytometry analysis showed that in WEHI-3B cells, 98% of the total GFP þ cell population expressed cell-surface GM-CSF after the cells were transduced with tmGM-CSF/GFP (Figure 2a , bottom panel). In contrast, only 3% of the GFP þ cell population transduced with unmodified GM-CSF contained cell-surface GM-CSF (Figure 2b , bottom panel). In addition, ELISA showed that relatively high amounts of GM-CSF (500 ng/ml) were detected in the cell culture medium from WEHI-3B Vaccination with GM-CSF-associated leukemia cells X Ling et al cells transduced with unmodified GM-CSF cDNA, whereas very low levels of GM-CSF (33 ng), which was comparable in level to non-transduced cells, were detected in the culture medium from the cells transduced with tmGM-CSF cDNA (Figure 2c ). Figure 2d shows that cells transduced with CD40L/GFP cDNA expressed CD40L on the surface of the cells (left panel), as determined by red fluorescence originating from cells incubated with phycoerythrin (PE)-labeled anti-CD40L. Figure 2d (right panel) shows the same view of these cells detected by green fluorescence due to GFP expression.
Murine leukemia models
After challenging mice with either WEHI-3B or WEHI-3B/GFP þ cells, or BCR-ABL þ 32D or BCR-ABL þ 32D/GFP cells, mice died of leukemia within 30-40 days (Figure 3a and b). No significant difference in mice survival was found between GFP þ and GFPÀ leukemia cells in both mouse strains (P>0.05 for both strains), indicating that GFP did not significantly alter the protective response to the WEHI-3B cells in BALB/c mice and to BCR-ABL þ 32D cells in C3H/HEJ mice. Fluorescent microscopy of tissues from leukemic mice revealed a significant invasion of spleen tissues by GFP þ cells (50-80% GFP þ cells) and a high level of GFP þ cells in the peripheral blood (Table 1 ). In addition, enlarged spleens were observed in both WEHI-3B leukemia and BCR-ABL þ 32D leukemia models (Figure 3c and d). We also adapted the more aggressive BCR-ABL þ myeloid cell line (DA1-3b), which can also engraft in C3H/HeJ mice without pre-conditioning (Vereecque et al., 1999) (Figure 4c ).
Vaccine studies
In the BALB/c model, mice vaccinated with lethally irradiated WEHI-3B cells expressing tmGM-CSF led to a 100% protection (Figure 4a ) (the difference is significant, Po0.01), whereas mice vaccinated with lethally irradiated WEHI-3B cells expressing CD40L led to an 80% protection (Figure 4a ) (the difference is significant, Po0.05). These results are representative of three independent experiments. For the C3H model, a 60% protection was achieved when mice were vaccinated with tmGM-CSF-expressing 32D/Bcr-Abl cells (Figure 4b ) (the difference is significant, Po0.05). In a second experiment, four of six mice were protected by the tmGM-CSF/32D P210 cells vaccine. However, in a more aggressive BCR-ABL model (the BCR-ABL þ DA1 cell line termed DA1-3b), we achieved a significant delay (Po0.05) in death after vaccination with lethally irradiated tmGM-CSF-expressing DA1-3b cells ( Figure 4c ). Importantly, 60% survival was observed in the WEHI-3B mouse model when the vaccination was carried out after leukemia induction (Figure 4d ) (the difference is significant, Po0.01). For determining whether immune system is involved in this protection, a similar experiment was conducted in BALB/c nude mice. Vaccination of nude mice did not allow protection from the WEHI-3B/GFP challenge ( Figure 4e ). Vaccination with GM-CSF-associated leukemia cells X Ling et al ) (expressing tmGM-CSF/GFP, CD40L/green fluorescent protein (GFP) or GFP) were injected into the leg flanks of BALB/c mice (five mice per group) three times at intervals of 7 days, and all groups were challenged with WEHI-3B/GFP cells at 7 days after the final vaccination. (b) Vaccination of C3H/HEJ mice with lethally irradiated BCR-ABL þ 32D/GFP cells expressing tmGM-CSF protects mice from leukemia. Lethally irradiated cells (1 Â 10 6 ) (BCR-ABL þ 32D/tmGM-CSF/GFP, BCR-ABL þ 32D/GFP, BCR-ABL þ 32D 32D/tmGM-CSF/GFP, 32D/GFP) were injected into the flank two times at 7-day intervals. Seven days later, all mice were challenged with BCR-ABL þ 32D/ GFP cells. (c) Vaccination of C3H/HEJ mice with lethally irradiated DA1-3b cells expressing tmGM-CSF significantly delayed death due to leukemia. Mice were vaccinated three times with 10 6 DA1-3b lethally irradiated cells expressing tmGM-CSF. Mice were challenged with 1 Â 10 4 DA1-3b cells. (d) Vaccination with lethally irradiated WEHI-3b cells expressing tmGM-CSF after challenge with WEHI-3b/GFP leukemia cells protects 60% of mice from leukemia. Vaccinations were administered three times at the indicated days after leukemia induction in BALB/c mice. Pathology examination showed that all surviving mice in the vaccination group contained normal spleen and blood parameters (data not shown). (e) Vaccination did not protect nude mice from leukemia challenge. A similar vaccine experiment using vaccination with lethally irradiated WEHI-3B cells expressing tmGM-CSF was carried out in BALB/c nude mice.
Vaccination with GM-CSF-associated leukemia cells X Ling et al
We examined spleen and marrow of mice challenged with WEHI-3b/GFP cells with and without vaccination as above ( Figure 5 ). Spleen and marrow cell suspensions were analysed by fluorescent and phase-contrast microscopy. Unvaccinated mice developed enlarged spleens and marrow, which showed high levels of GFP þ WEHI-3b cells (Figure 5a and b) . In contrast, spleen and marrow from vaccinated mice were normal in appearance. Importantly, no GFP þ cells were detected in the spleen and marrow cell suspensions from vaccinated mice at 82 days post-challenge (Figure 5e and f). However, we cannot exclude the presence of a very small number of dormant leukemia cells (Saudemont et al., 2005) .
CD8 þ T cells are required for protection induced by lethally irradiated WEHI-3B cells expressing tmGM-CSF Five mice were depleted of either CD4 þ or CD8 þ T cells by injecting the mice with the appropriate monoclonal antibody after vaccination but before leukemia cell challenge. The results indicate that all mice depleted of CD8 þ T cells died after leukemia induction ( Figure 6 ). In contrast, only 20% of mice depleted of CD4 þ T cells died after the leukemia challenge ( Figure 6 ). The difference between the two groups is significant (Po0.01). The difference between CD4 þ -depleted/vaccinated group and non-vaccinated group is not significant (P>0.3). Thus, the successful vaccination of BALB/c mice cells with lethally irradiated leukemia cells containing cell-surface tmGM-CSF requires CD8 þ T cells, but depletion of CD4 þ T cells had little effect, although CD4 þ T cells appeared to be required for optimum protection.
Transplantation of spleen cells from vaccinated mice confers protection to challenge with WEHI-3B cells Five non-vaccinated mice were injected through tail vein with 2 Â 10 6 splenic cells isolated from vaccinated mice (same strain). The leukemia challenge was carried out 1 day after splenic cell transplantation. The results showed that 80% of the mice (four of five) that received the splenic cells from the vaccinated mice were protected from a lethal challenge, whereas mice transplanted with splenic cells from non-vaccinated mice were not protected from the leukemia cell challenge (Figure 7 ). Depletion of CD8 þ T cells from mice vaccinated with lethally irradiated WEHI-3B cells expressing the cell surface transmembrane form of GM-CSF prevented protection of mice from leukemia cell challenge. Depletion of either CD8 þ T cells or CD4 þ T cells was carried out in vaccinated mice as described in Materials and methods. The difference between the two groups is significant (Po0.01). The difference between CD4 þ -depleted/ vaccinated group and non-vaccinated group is not significant (P>0.30).
The difference between survival of mice transplanted with splenic cells from the non-vaccinated group and the vaccinated group was significant (Po0.05). There was no significant difference in survival between the vaccinated splenic cell transplantation group and the vaccinated group (P>0.1).
Discussion
In our studies, we have shown that the vaccination of immunocompetent mice (BALB/c and C3H/HEJ mice) with the murine leukemia cell lines that expressed murine cell-surface tmGM-CSF protected them from leukemia challenge, either completely (the WEHI model; Figure 4a ) or about 65% for the BCR-ABL þ 32D/ C3H/HeJ (Figure 4b ). In the very aggressive DA1-3b model, death was significantly delayed by vaccination with tmGM-CSF/DA1-3b cells (Figure 4c) . We emphasize that the DA1-3b cell line is reported to be deficient in costimulatory and MHC molecules, which would imply a deficiency in self-antigen presentation to the immune system (Vereecque et al., 1999) . This deficiency in immune presentation would correlate with the aggressive behavior of this cell line and may explain the lack of protection (we observed 65% for BCR-ABL þ 32D cells; Figure 4b ) and just an increased survival with the DA1-3b system (Figure 4c ).
To our knowledge, this is the first report that mice vaccinated with leukemic cells expressing tmGM-CSF can achieve such high level of protection from leukemia. de Vos et al. (1998) reported that expression of soluble GM-CSF provided only a low degree of protection (20%) in vaccine experiments with WEHI-3B cell line. Most importantly, we were able to show a 60% therapeutic effect by using vaccination with the WEHI-3B leukemic cells that express a membraneanchored GM-CSF (Figure 4d ). Our CD4 þ and CD8 þ T cells depletion experiments with the WEHI-3B/BALB/c mice ( Figure 6 ) and experiments with splenic cells derived from WEHI-3B-vaccinated mice (Figure 7) indicate that (1) CD8 þ cells are required for achieving a protective immune response because specific CD8 þ cell depletion from vaccinated mice eliminated the protection induced by the vaccination process, (2) the protective cellular immunity to the leukemia cells is transplantable because intravenous injection of splenic cells from vaccinated mice into non-vaccinated mice protected 80% of the mice from the leukemia cell challenge. We, therefore, conclude that modifying leukemia cells to express cell-surface tmGM-CSF can in some cases (e.g. the WEHI-3B leukemia cell) overcome immune tolerance to the leukemia cell.
In order to compare the effects of tmGM-CSF with another membrane-bound cytokine that is reported to have protective effects (Saudemont et al., 2002) , we performed similar vaccine experiments with CD40L. We found that vaccination with WEHI-3B cells that express CD40L also had a strong protective effect, although the level of protection was lower (80% of vaccinated mice survived) (Figure 4a ) than that with WEHI-3B cells expressing cell-surface tmGM-CSF.
Natural killer (NK) cells have been implicated in the DA1-3b cell system as being important to eliminate dormant leukemia cells (Saudemont et al., 2005) . Their studies indicate that NK cells activated by the chemokine CXCL10 can kill dormant DA1-3b cells that are resistant to CTL-mediated lysis. In our experiments with the DA1-3b system, we induced a significant delay in death in mice vaccinated with tmGM-CSF/DA1-3b cells, which suggests that activation of NK cells in this model would increase survival of the vaccinated mice. In this regard, we note that healthy mice vaccinated with irradiated tmGM-CSF/WEHI-3B/GFP cells did not have detectable dormant leukemia cells in their spleens and marrow after 82 days following challenge with WEHI-3B/GFP cells ( Figure 5 ). In addition, NK activity was not protective in our vaccine experiments conducted with nude mice (Figure 4e ), which are known to have functional NK cells.
In our vaccine studies, GFP was used as the biomarker for gene transduction and cell sorting. It was reported that GFP is an immunogen for C57BL/6 and BALB/c mice in tumor studies (Gambotto et al., 2000; Stripecke et al., 2001) . In contrast, others have failed to reproduce these findings (Denaro et al., 2001 ). In our study, GFP did not cause any significant host immune response to WEHI-3B cells in BALB/c mice (Figures 3 and 4b) .
The lentivirus gene delivery system has some advantages that make it superior to other gene transduction systems (Naldini et al., 1996; Miyoshi et al., 1998) . Substitution of the vesicular stomatitis virus G envelope protein in place of the HIV envelope protein provides the lentivirus with an ability to infect many cell types with high efficiency (Naldini et al., 1996) , especially hematopoietic cells, which are usually difficult to be Figure 7 Transplantation of splenic cells from mice vaccinated with lethally irradiated WEHI-3B cells expressing cell-surface transmembrane form of GM-CSF factor protected recipient mice from WEHI-3B cell challenge. Each of five non-vaccinated mice received 2 Â 10 6 of Ficol fractionated splenic cells enriched for monocytes (including T cells) isolated from vaccinated mice (same strain) through tail vein injection. The leukemia challenge was carried out 1 day after the splenic cell transplantation. The difference in survival between mice from the vaccine splenic cell transplantation group and those from the non-vaccinated group was significant (Po0.05). There was no significant difference in survival between the splenic cell transplantation group and the vaccinated group (P>0.10).
Vaccination with GM-CSF-associated leukemia cells X Ling et al transduced by other gene delivery methods (Naldini et al., 1996; Ling et al., 2003) . In addition, the lentivirus gene transfer method allows the gene of interest to be expressed for a prolonged period of time because of DNA integration. Prolonged gene expression also provides sufficient time for selection of the infected cell (using GFP expression as the marker for infection), and for expansion of the transduced cells after the initial gene transfer step. Many studies have indicated that a strong immune response to a particular antigen is largely dependent on an efficient activation of antigen-presenting cells, such as DCs. In vitro studies have shown that GM-CSF is one of the strongest stimulators of DC maturation (Larregina et al., 1996; Menetrier-Caux et al., 1998; Soo Hoo et al., 1999; Yei et al., 2002) . Our findings of protection from leukemia cell challenge in immunocompetent mice vaccinated with leukemic cells expressing tmGM-CSF suggest involvement of DCs as part of the protective response, which would possibly maximize the direct interaction between the leukemia cell and the DCs that express the GM-CSF receptor. Importantly, these results provide strong evidence to support the hypothesis that this approach can be developed as an alternative treatment for leukemia in humans.
Materials and methods

Antibodies
Phycoerythrin-labeled rabbit anti-mouse CD40L antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-rat GM-CSF antibody was from BD (San Jose, CA, USA). Phycoerythrin-labeled goat anti-rat IgG was from Southern Biotechnology (Birmingham, AL, USA). The GM-CSF ELISA kit was from Pierce (Rockford, IL, USA). Anti-CD4 and -CD8 antibodies were produced by injecting the hybridomas (ATCC, CRL-1971 for CD8 and TIB-207 for CD4) into mice, the ascites was collected and the antibodies were purified as described (Matulonis et al., 1995) . After the purification, the antibodies were dialysed against 0.9% of NaCl.
Mice Pathogen-free female BALB/c and C3H/HEJ mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA), and maintained in the MD Anderson Cancer Center animal facility. BALB/c nu/nu nude mice were purchased from Charles River (Wilmington, MA, USA).
293T cells 293T cells are human embryonic kidney epithelia obtained from ATCC and maintained in Dulbecco's modified Eagles's medium (DMEM) with 10% of fetal bovine serum (FBS).
Murine leukemia cells WEHI-3B cells were obtained from ATCC (Rockville, MD, USA); they induce a fatal acute myelomonocyte leukemia in BALB/c mice. These cells are non-immunogenic and express class I MHC molecules (de Vos et al., 1998) . We transduced GFP into these cells by lentivirus infection. Green fluorescent protein serves as a marker to monitor the leukemia development in mice. The cells were maintained in DMEM plus 10% FBS. BCR-ABL þ 32D cells were obtained from the laboratory of Bruno Calabreta. The 32D cell line (clone 3) was derived from C3H/HEJ mice (Greenberger et al., 1983) , and human BCR-ABL oncogene (b3/a2)gene was transduced into 32D cell line (Daley et al., 1990) . BCR-ABL þ 32D cells induce leukemia on injecting 6-8-week-old C3H/HEJ mice (Matulonis et al., 1995) . Green fluorescent protein was transduced into these cells by lentivirus infection. This cell line was maintained in DMEM plus 10% FBS. A second BCR-ABL mouse leukemia model, the DA1-3b/C3H-HEJ system, was also employed (Vereecque et al., 1999) . Both DA1-3b (BCR-ABL þ ) and DA1 cells were kindly provided by Dr Quesnel (Lille, France). DA1-3b cells induce an aggressive murine leukemia in C3H mice (Vereecque et al, 1999) . These cells were maintained in PRMI 1640 plus 10% FBS.
Mouse leukemia induction
For BALB/c mouse leukemia model, WEHI-3B or WEHI-3B/ GFP cells were washed three times with PBS. 5 Â 10 4 cells/ 100 ml were injected into each mouse through tail vein. Injected mice were monitored for leukemia development and survival. For C3H/HEJ mouse leukemia model, BCR-ABL þ 32D or BCR-ABL þ 32D/GFP cells were washed three times with PBS. 1 Â 10 6 cells/100 ml were injected into the mouse through tail vein. Injected mice (five mice) were monitored for leukemia development and survival. In addition, 1 Â 10 4 cells/100 ml of DA1-3b were injected by the tail vein of C3H/HEJ mice.
Lentivirus gene transfer vectors
Three lentivirus gene transfer vectors for murine GM-CSF, tmGM-CSF and CD40L were constructed as described below. Lentivirus GM-CSF and CD40L gene transfer vectors were constructed by performing PCR to add SmaI and BamHI sites to GM-CSF cDNA and SmaI and BgII sites to CD40L cDNA. The template for murine GM-CSF was pORF/GM-CSF plasmid (Invivogen, San Deigo, CA, USA). The template for murine CD40L was a plasmid provided by Dr Thomas Kipps (UCSD, San Diego, CA, USA). After insertion into pTOPO, the DNA sequence was confirmed; a SmaI/SalI GM-CSF fragment was cleaved from pTOPO and inserted into pDisplay vector (Invitrogen) at the SmaI/SalI site to provide a 5 0 leader and a 3 0 transmembrane domain linked to GM-CSF. The 5 0 leader-GM-CSF-tm-3 0 fragment was released from the pDisplay plasmid with SmaI and EagI. After filling in the EagI at the 3 0 end, the fragment was inserted into the lentivirus gene transfer vector at the SmaI site, and the clone with correct orientation was confirmed by sequencing. Figure 1a -c shows the structures of the three plasmids. We used an internal EF-1a promoter to drive gene expression in hematopoietic cells. The resulting PCR products of GM-CSF and CD40L constructs were separately inserted into the lentivirus gene transfer vector (a gift from Dr D Trono). Sequencing was performed to confirm the correct sequence of all constructs.
Lentivirus preparation
Lentiviruses were prepared by transfecting three plasmids into 293T cells as described in Miyoshi et al. (1998) and Ling et al. (2003) .
Gene transfer tmGM-CSF, GM-CSF, CD40L and GFP cDNAs were transduced into target cells by infection with a bicistronic lentivirus encoding an IRES and GFP downstream of the cDNA insert according to the method described elsewhere (Bahnson et al., 1995; Miyoshi et al., 1998; Ling et al., 2003) .
Vaccination with GM-CSF-associated leukemia cells X Ling et al GM-CSF-, tmGM-CSF-or CD40L-positive WEHI-3B cell selection Because of the bicistronic design of the gene transfer vector (Figure 1a-c) , lentivirus-infected cells will express the gene of interest and GFP. Thus, WEHI-3B cells and BCR-ABL þ 32D cells that express either GM-CSF, tmGM-CSF or CD40L were sorted by using GFP as a fluorescent marker and the cells were expanded.
Vaccination and challenge with leukemia cells Either cytokine-expressing or GFP-only-expressing leukemia cells were lethally irradiated at 150 Gy (irradiator: US Nuclear, model # EO103, Burbank, CA, USA). After three washes with PBS, the irradiated cells were injected into the mouse flank subcutaneously (10 6 cells/100 ml). Two to three vaccinations were given at 7-day intervals. Seven days after the last vaccination, mice were challenged with either WEHI-3B/ GFP cells (10 6 cells/100 ml) or BCR-ABL þ 32D/GFP cells (10 6 cells/100 ml) or DA1-3b cells (10 4 cells/100 ml) by tail vein injection. Mice were monitored for development of leukemia and survival.
CD4 þ and CD8 þ T-cell depletion Purified CD4 and CD8 antibody was injected into mouse through the tail vein. For CD8 þ T-cell depletion, each mouse was injected with 350 mg Ig protein, and for CD4 þ T-cell depletion, each mouse was injected with 500 mg Ig. Three injections were carried out in total; each injection was performed 1 day after vaccination.
Splenic cells transplantation
Vaccinated mice were killed 7 days after the last vaccination, and splenic cells were isolated by Ficol gradient separation (Histopaque cat. #10771, Sigma-Aldrich, St Louis, MO, USA) to enrich for monocytes. Each mouse was injected with 2 Â 10 6 splenic cells 1 day before the leukemia cell challenge.
Analysis of spleen and marrow tissues A suspension of spleen cells was prepared and examined under a fluorescent microscope to detect WEHI-3B GFP-positive leukemia cells. Similarly, marrow cells were extruded from a fresh femur to prepare a cell suspension in PBS. Cells were processed immediately for phase-contrast and fluorescent microscopy ( Â 20 magnification).
